BenevolentAI
BenevolentAI · Coding · Business
BenevolentAI is a London-founded AI drug discovery company. Its biomedical knowledge graph powers target identification and now drives Qor, an evidence-linked decision platform.
About BenevolentAI
What Is BenevolentAI
BenevolentAI is a life sciences technology company that applies machine learning to biomedical evidence. Founded in London in 2013, it spent a decade building a biomedical knowledge graph: a structured map of genes, proteins, diseases, compounds, patents and papers that its models can reason over.
That graph is the core asset. Drug hunters normally read the literature by hand and hold the connections in their heads. BenevolentAI turned those connections into a queryable layer, then used it for target identification in diseases where the biology is messy, such as chronic kidney disease and idiopathic pulmonary fibrosis.
The company listed on Euronext Amsterdam in 2022 and delisted in March 2025 through a merger into Osaka Holdings. Drug discovery setbacks, including the discontinued BEN-2293 programme for atopic dermatitis, forced a narrower focus. Today the same drug discovery platform is sold as Qor, a decision platform for biotech teams, consultancies and investors. There is no public price list, and the deep discovery work runs through partnerships rather than a self-serve product.
Getting Started
- Open qor.one and request a free trial or book a demo with the team.
- Name the asset or indication you care about, plus the decision you have to defend, such as a partnering case or a funding round.
- Let the platform pull the evidence set and draft the position, then check each claim against its cited source.
- Save the position and set alerts so you see what changed since the last review.
- For drug discovery collaborations, contact BenevolentAI directly; those engagements are scoped with the science team.
Product Information
A quick look at BenevolentAI's pricing, supported platforms, and performance.
Best for
The users, tasks, and scenarios where this tool fits best.
Users
- Preclinical founders
- Clinical stage executives
- Life science consultants and investors
Tasks
- Target identification in complex disease
- Competitive positioning
- Partnering and deal work
Scenarios
- Preparing a board briefing
- Watching a fast-moving indication
- Early research on an unfamiliar disease area
Key features
Biomedical Knowledge Graph
BenevolentAI's graph links genes, proteins, pathways, diseases, compounds and published findings into one structure that models can traverse. It was built over more than a decade with in-house ontologies, which is why the company treats it as the moat rather than the model layer. For a research team, the practical effect is that a question about an unfamiliar target returns connected evidence instead of a list of papers.
Target Identification for Complex Diseases
The platform was designed for diseases where single-gene thinking fails, and its public track record sits in chronic kidney disease, idiopathic pulmonary fibrosis, heart failure and lupus. Scientists at AstraZeneca selected several BenevolentAI-derived targets for their own pipeline after a collaboration that began in 2019. According to BenevolentAI, those targets came from graph reasoning over curated literature and experimental data, not from a single screening campaign.
Qor: Evidence-Linked Answers
Qor is the current commercial face of the technology. You ask a question about an asset or an indication and get a structured position covering the field, the implications and what changed. Each factual claim passes a source verification step before it reaches you, which is the main difference from pointing a general chatbot at the same question.
Continuous Monitoring Instead of One-Off Reports
Most research deliverables expire the day they are delivered. Qor keeps each saved position under review and rechecks it as new papers, trial readouts and deals appear. When a competitor discontinues a programme, the update lands without anyone remembering to look, which is the failure mode analysts describe most often.
Workflows Shaped by Deal and Portfolio Decisions
The product is organised around the questions biotech leaders actually face: how crowded is this indication, what did comparable assets sell for, does a rival readout help or hurt our case, and does the analysis still hold. That framing came from building with scientists, investors and consultants rather than from a generic document assistant.
Partnership Model for Discovery Programmes
Deeper discovery work runs through collaborations with pharmaceutical companies, where BenevolentAI scientists and partner scientists work the same disease area together. The AstraZeneca relationship expanded in 2022 to cover heart failure and systemic lupus erythematosus, and it remains the clearest example of how the platform gets used beyond a report.
Pros and cons
Pros
- The biomedical knowledge graph is a genuine long-term asset, with ontologies and curation work that a competitor cannot copy quickly.
- Target identification output comes with traceable evidence, so a scientist can audit the reasoning instead of trusting a score.
- Qor keeps answers current, which addresses the usual problem of analysis that goes stale the week it ships.
- The company has real pharma validation: AstraZeneca moved multiple AI-derived targets into its pipeline.
- A free trial path lets a small team test the workflow before any commercial conversation.
Cons
- There is no public pricing, so budgeting means a sales conversation and a custom quote.
- Clinical setbacks are part of the record; BEN-2293 missed its Phase IIa endpoints and the programme was dropped.
- The product assumes domain knowledge. A general user without biology background will struggle to judge whether an answer is any good.
- Discovery collaborations are slow, contract-heavy engagements, so a small biotech cannot simply buy access to the full engine.
Frequently asked questions
It is used to find and rank drug targets in complex diseases and to support decisions around assets, competitors and deals. The discovery work happens in pharma partnerships; the decision work is sold as Qor.
Related content
Explore related tools, skills, and articles for BenevolentAI.
BenevolentAI Alternatives
Base Code
Base44 (Wix) · Coding · ProductivityBase Code is a shared cloud development environment from Base44. Teammates describe changes to an existing GitHub codebase in chat, preview them live and send them back as pull requests.
Google EmbeddingGemma 2
Google DeepMind · Writing · Image · CodingGoogle EmbeddingGemma 2 is a 740M-parameter open model that turns text, code, images, audio, and video frames into vectors in one 768-dimension space, running on phones and laptops.
GitGlow
GitGlow · Coding · ProductivityGitGlow is a local-first desktop Git client that lets independent developers review their own code and their AI agents' changes in one place before shipping.